Why Moderna Has More Upside Than Its Covid-19 Vaccine Implie

Why Moderna Has More Upside Than Its Covid-19 Vaccine Implies
InvestorPlace
1/15/2021
Last month, ahead of the release of its novel coronavirus vaccine to combat the coronavirus,
Moderna (NASDAQ:
MRNA) traded as high as $178.50. Frantic buying and selling rewarded momentum traders. So, when Moderna stock traded in the range of $140 to $165, day-traders locked in gains.
© Provided by InvestorPlace
The Moderna (MRNA) logo surrounded by syringes, pills and disposable face masks.
The heightened volatility did not last. By mid-Dec., 2020, Moderna shares broke down below its 20-day simple moving average.
Now that the stock is starting to attract buyers, what will it take for the uptrend to hold this time?

Related Keywords

India , Israel , Investorplace Moderna , Moderna Covid , Ascannio Shutterstock , Pfizer , Astrazeneca , National Institute Of Health , European Commission , Ministry Of Health , Israel Ministry Of Health , Investorplace The Moderna , Stock Worth Almost , Wall Street , Metricsrangeconclusion Discount Rate , Perpetuity Growth Rate , Fair Value , National Institute , இந்தியா , இஸ்ரேல் , ஃபைசர் , தேசிய நிறுவனம் ஆஃப் ஆரோக்கியம் , ஐரோப்பிய தரகு , அமைச்சகம் ஆஃப் ஆரோக்கியம் , இஸ்ரேல் அமைச்சகம் ஆஃப் ஆரோக்கியம் , ஸ்டாக் மதிப்பு கிட்டத்தட்ட , சுவர் தெரு , நியாயமான மதிப்பு , தேசிய நிறுவனம் ,